WallStSmart

Bausch + Lomb Corp (BLCO)vsMedline Inc. Class A Common Stock (MDLN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 460% more annual revenue ($29.14B vs $5.21B). MDLN leads profitability with a 3.3% profit margin vs -4.2%. MDLN earns a higher WallStSmart Score of 52/100 (C-).

BLCO

Hold

44

out of 100

Grade: D

Growth: 5.3Profit: 3.0Value: 5.0Quality: 4.5
Piotroski: 2/9Altman Z: 0.91

MDLN

Buy

52

out of 100

Grade: C-

Growth: 7.3Profit: 5.5Value: 4.7Quality: 6.5
Piotroski: 4/9Altman Z: 1.70
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BLCOSignificantly Overvalued (-78.0%)

Margin of Safety

-78.0%

Fair Value

$9.57

Current Price

$15.26

$5.69 premium

UndervaluedFair: $9.57Overvalued

Intrinsic value data unavailable for MDLN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BLCO2 strengths · Avg: 9.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

PEG RatioValuation
0.898/10

Growing faster than its price suggests

MDLN3 strengths · Avg: 9.0/10
EPS GrowthGrowth
1258.0%10/10

Earnings expanding 1258.0% YoY

Market CapQuality
$65.23B9/10

Large-cap with strong market position

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Areas to Watch

BLCO4 concerns · Avg: 2.5/10
Operating MarginProfitability
4.7%3/10

Operating margin of 4.7%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-3.4%2/10

ROE of -3.4% — below average capital efficiency

EPS GrowthGrowth
-88.6%2/10

Earnings declined 88.6%

MDLN4 concerns · Avg: 3.5/10
P/E RatioValuation
32.1x4/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.704/10

Distress zone — elevated risk

Profit MarginProfitability
3.3%3/10

3.3% margin — thin

Debt/EquityHealth
1.123/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : BLCO

The strongest argument for BLCO centers on Price/Book, PEG Ratio. PEG of 0.89 suggests the stock is reasonably priced for its growth.

Bull Case : MDLN

The strongest argument for MDLN centers on EPS Growth, Market Cap, Price/Book. Revenue growth of 10.7% demonstrates continued momentum.

Bear Case : BLCO

The primary concerns for BLCO are Operating Margin, Piotroski F-Score, Return on Equity.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Altman Z-Score, Profit Margin. Thin 3.3% margins leave little buffer for downturns.

Key Dynamics to Monitor

BLCO profiles as a turnaround stock while MDLN is a value play — different risk/reward profiles.

MDLN is growing revenue faster at 10.7% — sustainability is the question.

MDLN generates stronger free cash flow (316M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDLN scores higher overall (52/100 vs 44/100) and 10.7% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bausch + Lomb Corp

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Bausch Lomb Corporation is an eye health company in Canada and internationally. The company is headquartered in Vaughan, Canada.

Visit Website →

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

Want to dig deeper into these stocks?